RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

IMS Health Incorporated

A collection of news and information related to IMS Health Incorporated published by this site and its partners.

Top IMS Health Incorporated Articles

Displaying items 12-22
  • Diabetes 'massive challenge' as cases hit 366 million

    Diabetes 'massive challenge' as cases hit 366 million
    LONDON (Reuters) - The number of people living with diabetes has soared to 366 million, and the disease kills one person every seven seconds, posing a "massive challenge" to healthcare systems worldwide, experts said on Tuesday. The vast majority of...
  • Diabetes cases hit record and half go undiagnosed

    Diabetes cases hit record and half go undiagnosed
    LONDON (Reuters) - Diabetes is running at record levels worldwide and half the people estimated to have the disease are, as yet, undiagnosed, according to a report on Wednesday. The number of people living with diabetes is now put at 371 million, up from...
  • Sleeping pills linked to higher risk of cancer, death, study says

    Sleeping pills linked to higher risk of cancer, death, study says
    A new study suggests that the 6% to 10% of Americans who use prescription sleep medications such as zolpidem (Ambien), temazepam (Restoril), eszopiclone (Lunesta) and zaleplon (Sonata) are more likely to develop cancer, and far more likely to die...
  • The Big One is going generic

     
    The nation's largest-selling pharmaceutical is going generic this week. Lipitor, which is prescribed to help people reduce their cholesterol levels, is going "off-patent" Wednesday. According to a HealthDay News report, Lipitor sales were nearly $4...
  • Newer antipsychotics overused, US study suggests

    Newer antipsychotics overused, US study suggests
    Although first approved to treat schizophrenia, new antipsychotic medications are increasingly being prescribed for a host of other uses, even when there is little evidence they work, U.S. researchers said on Friday. The drugs, known as "atypical...
  • Benefits of hormones unclear

    Benefits of hormones unclear
    In a quest to look younger, be healthier and feel more vital later in life, increasing numbers of men, just like Jeffry Life, are turning to testosterone and human growth hormone. Use of both hormones is controversial. Read on: Testosterone: "Older men ....
  • 'Female Viagra' Falls Short

    'Female Viagra' Falls Short
    A pink pill designed to boost sex drive in women - the latest attempt by the drug industry to find a female equivalent to Viagra - fell short in two studies, federal health regulators said Wednesday. The Food and Drug Administration is considering...
  • FDA: Avandia Should Stay With Restrictions

    FDA: Avandia Should Stay With Restrictions
    Faced with conflicting and less-than-conclusive scientific evidence, a Food and Drug Administration advisory panel recommended Wednesday that the controversial diabetes drug Avandia remain on the market — but with tighter supervision and increased...
  • Sleeping pill use grows as economy keeps people up at night

    Sleeping pill use grows as economy keeps people up at night
    Lost jobs and lost careers. Promising businesses in shambles. The college acceptance letter returned to its envelope. This is how President Obama recently described the effect of the tanking economy on ordinary Americans -- and the stresses keeping them...
  • Effectiveness of statins called into question

    Effectiveness of statins called into question
    As the world's most-prescribed class of medications, statins indisputably qualify for the commercial distinction of "blockbuster." About 24 million Americans take the drugs — marketed under such commercial names as Pravachol, Mevacor, Lipitor, Zocor...
  • Use of atypical antipsychotics for lesser disorders is gaining ground, despite safety concerns

    Use of atypical antipsychotics for lesser disorders is gaining ground, despite safety concerns
    About a year ago, patients began trooping into the office of UCLA psychiatrist Andrew Leuchter, asking whether an antipsychotic drug called Abilify "might be right for them." Few appeared to be delusional, plagued by hallucinations or suffering fearsome...